Researchers make neuroblastoma drug target discovery
February 8, 2021Sales and Marketing Cancer, GOSH, neuroblastoma
Scientists conducting the largest single cell study to date of the childhood cancer neuroblastoma have made a breakthrough in identifying …
CureVac enters collaboration with UK government on coronavirus variant vaccines
February 8, 2021Sales and Marketing COVID-19, CureVac
CureVac has entered a collaboration with the UK government to develop and manufacture potential vaccine candidates against coronavirus variants, with …
South Africa halts rollout of AstraZeneca’s COVID-19 vaccine amid efficacy concerns
February 8, 2021Sales and Marketing AstraZeneca, COVID-19
AstraZeneca is racing to adapt its COVID-19 vaccine as new data suggests it offers little protection against the more dominant …
South Korea approves Celltrion’s COVID-19 treatment Regdanvimab for emergency use
February 8, 2021Sales and Marketing COVID-19, celltrion
The South Korean Ministry of Food and Drug Safety (MFDS) has granted a conditional marketing authorisation (CMA) for the emergency …
Pharmafile.com’s top 10 news stories of the week
February 5, 2021Medical Communications COVID-19
In the last week, a number of COVID-19 vaccine developments have been made. Johnson & Johnson’s one-shot jab was found …
New Oxford University-AstraZeneca vaccine against COVID-19 mutations could be available by October
February 5, 2021Medical Communications AstraZeneca, COVID-19
Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 …
Pfizer withdraws application for emergency vaccine authorisation in India
February 5, 2021Medical Communications COVID-19, Pfizer
Pfizer has withdrawn its application in India for emergency use authorisation of its vaccine, which it has produced with German …
Hyloris and Purna Female Healthcare partner to develop novel women’s health product
February 5, 2021Medical Communications Hyloris, women
Hyloris Pharmaceuticals and Purna Female Healthcare (PFH), a spin-off founded by Purna Pharmaceuticals and Creafund, have entered into a partnership …
AstraZeneca’s Imfinzi misses target in Phase III head and neck cancer trial
February 5, 2021Medical Communications AstraZeneca, Cancer
AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer …
Destiny Pharma appoints Professor Mark Wilcox to its Scientific Advisory Board
February 4, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening …
Scripps Research and IAVI report positive findings from HIV vaccine Phase I trial
February 4, 2021HIV
Scripps Research and IAVI have returned positive Phase I results in their hunt for a HIV vaccine, detecting a targeted …
China approves AstraZeneca’s heart failure drug Forxiga
February 4, 2021AstraZeneca, Forxiga
AstraZeneca’s Forxiga (dapagliflozin) has been approved for use in China to reduce the risk of death and hospitalisation from heart …
Raremark appoints Caroline O’Connor as CCO
February 4, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer. Previously holding the position of Raremark’s Senior Vice President …
Pfizer and Imcyse enter research and licence agreement for rheumatoid arthritis programme
February 4, 2021Imcyse, Pfizer
Imcyse has entered into a research collaboration and licence agreement with Pfizer for Imcyse’s rheumatoid arthritis (RA) programme based on …
NICE recommends MSD’s Keytruda in combination with chemotherapy for lung cancer
February 4, 2021Cancer, MSD
NICE has recommended MSD’s Keytruda (pembrolizumab) with pemetrexed and platinum chemotherapy (pembrolizumab combination) as a first-line option for untreated, metastatic, …
Jazz acquires GW Pharmaceuticals in $7.2 billion deal
February 4, 2021cannabinoid, jazz pharmaceuticals
Jazz Pharmaceuticals has acquired GW Pharmaceuticals for over $7 billion, with the transition expected to close in the second quarter …
Pharmafile.com’s weekly COVID-19 news round-up
February 3, 2021Research and Development COVID-19
The past week has seen mostly positive COVID-19 vaccine developments; Pfizer has confirmed its jab is effective against both the …
Longer Oxford-AstraZeneca vaccine interval improves efficacy, report says
February 3, 2021Research and Development AstraZeneca, COVID-19
A longer interval between doses of the Oxford University-AstraZeneca vaccine could substantially improve efficacy, according to a report published in …
GSK and CureVac sign £132m deal to develop next-generation COVID-19 vaccine
February 3, 2021Research and Development COVID-19, CureVac, GlaxoSmithKline
GlaxoSmithKline (GSK) and CureVac have today announced they are joining forces to develop a new COVID-19 vaccine to combat future …
CHMP recommends marketing authorisation for Incyte’s pemigatinib
February 3, 2021Research and Development EMA, Incyte
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Incyte’s pemigatinib for …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
